Literature DB >> 9113196

Alzheimer's disease: transiently developing dendritic changes in pyramidal cells of sector CA1 of the Ammon's horn.

E Braak1, H Braak.   

Abstract

In the course of Alzheimer's disease, specific CA1 pyramidal cells develop dendritic changes, which can only be observed transiently. Distal segments of the apical dendrite running through the stratum lacunosum-moleculare show spindle-shaped dilations filled with abnormal tau protein. The alteration eventually leads to amputation of the changed segment. The damage first appears at stage II in the evolution of the neurofibrillary changes [5], is best developed at stage III, and vanishes from the tissue at stage IV. It is usually not observed in stages V and VI (fully developed Alzheimer's disease).

Entities:  

Mesh:

Year:  1997        PMID: 9113196     DOI: 10.1007/s004010050622

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  54 in total

1.  Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease.

Authors:  E B Mukaetova-Ladinska; F Garcia-Siera; J Hurt; H J Gertz; J H Xuereb; R Hills; C Brayne; F A Huppert; E S Paykel; M McGee; R Jakes; W G Honer; C R Harrington; C M Wischik
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration.

Authors:  Tomasz Jaworski; Benoit Lechat; David Demedts; Lies Gielis; Herman Devijver; Peter Borghgraef; Hans Duimel; Fons Verheyen; Sebastian Kügler; Fred Van Leuven
Journal:  Am J Pathol       Date:  2011-08-10       Impact factor: 4.307

3.  A computational atlas of the hippocampal formation using ex vivo, ultra-high resolution MRI: Application to adaptive segmentation of in vivo MRI.

Authors:  Juan Eugenio Iglesias; Jean C Augustinack; Khoa Nguyen; Christopher M Player; Allison Player; Michelle Wright; Nicole Roy; Matthew P Frosch; Ann C McKee; Lawrence L Wald; Bruce Fischl; Koen Van Leemput
Journal:  Neuroimage       Date:  2015-04-29       Impact factor: 6.556

4.  APOE ε4 worsens hippocampal CA1 apical neuropil atrophy and episodic memory.

Authors:  Geoffrey A Kerchner; Daniela Berdnik; Jadon C Shen; Jeffrey D Bernstein; Michelle C Fenesy; Gayle K Deutsch; Tony Wyss-Coray; Brian K Rutt
Journal:  Neurology       Date:  2014-01-22       Impact factor: 9.910

5.  Electrophysiological changes precede morphological changes to frontal cortical pyramidal neurons in the rTg4510 mouse model of progressive tauopathy.

Authors:  Johanna L Crimins; Anne B Rocher; Jennifer I Luebke
Journal:  Acta Neuropathol       Date:  2012-09-14       Impact factor: 17.088

6.  Regional Tau Effects on Prospective Cognitive Change in Cognitively Normal Older Adults.

Authors:  Xi Chen; Kaitlin E Cassady; Jenna N Adams; Theresa M Harrison; Suzanne L Baker; William J Jagust
Journal:  J Neurosci       Date:  2020-11-20       Impact factor: 6.167

Review 7.  The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease.

Authors:  Johanna L Crimins; Amy Pooler; Manuela Polydoro; Jennifer I Luebke; Tara L Spires-Jones
Journal:  Ageing Res Rev       Date:  2013-03-22       Impact factor: 10.895

8.  Modeling of tau-mediated synaptic and neuronal degeneration in Alzheimer's disease.

Authors:  Tomasz Jaworski; Sebastian Kügler; Fred Van Leuven
Journal:  Int J Alzheimers Dis       Date:  2010-08-24

9.  Inactivation of presenilins causes pre-synaptic impairment prior to post-synaptic dysfunction.

Authors:  Dawei Zhang; Chen Zhang; Angela Ho; Alfredo Kirkwood; Thomas C Südhof; Jie Shen
Journal:  J Neurochem       Date:  2010-10-26       Impact factor: 5.372

Review 10.  Tau function and dysfunction in neurons: its role in neurodegenerative disorders.

Authors:  Jesús Avila; Filip Lim; Francisco Moreno; Carlos Belmonte; A Claudio Cuello
Journal:  Mol Neurobiol       Date:  2002-06       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.